Chandra Verma

Agency for Science, Technology and Research

Also affiliated with National University of Singapore, Nanyang Technological University, Université Bourgogne Franche-Comté, Bioinformatics Institute

Biochemistry, Genetics and Molecular BiologyMedicineMaterials Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology”.

Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology

Journal of Biological Chemistry(2020)10.1074/jbc.ra119.012056

N/A

0.691DataRank · unranked

19 citations

Gergana Popova, Andrés Pastor Fernández, Srinivasaraghavan Kannan, Ingeborg M.M. van Leeuwen, M. Håkansson +7 more

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0571

N/A

0DataRank · unranked

70 citations

Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman +29 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Rarγ-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer

EMBO Reports(2024)10.1038/s44319-024-00335-y

N/A

0DataRank · unranked

4 citations

Alessandro Alaimo, Davide Bressan, Sacha Genovesi, Elisa Marmocchi, Nicole Annesi +16 more

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors

Clinical and Translational Medicine(2025)10.1002/ctm2.70338

N/A

0DataRank · unranked

3 citations

Valentina Foglizzo, Jason Chang, Natasha Rekhtman, Ann Elizabeth Sisk, Jamie Gibson +20 more

FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

Cancer Cell(2020)10.1016/j.ccell.2020.08.003

N/A

0DataRank · unranked

140 citations

Jesper L.V. Mååg, Srushti Kittane, Yanyan Cai, Wouter R. Karthaus, Erik Ladewig +22 more

384 | PROGNOSTIC AND FUNCTIONAL IMPACT OF EGF‐JAK/STAT PATHWAY MUTATIONS IN ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA

Hematological Oncology(2025)10.1002/hon.70094_384

N/A

0DataRank · unranked

0 citations

Jing Quan Lim, Leonardo P. A. Biral, Chee Leong Cheng, Chandra Verma, Srinivasaraghavan Kannan +10 more